ClinicalTrials.gg
CompletedNCT01156792Updated Apr 5, 2017Results posted

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

A Phase 2 interventional study of FP 100 and GSK2190915 100 in Asthma, sponsored by GlaxoSmithKline. Completed at 32 sites in United States. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-04-05.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
12 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
99th of 238
162 · median 93
Started
2010
with 33 others
Phase 2
59 of 262
none open now
Registered
99th of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 99th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 59 in phase 2, and was the 99th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of adding GSK2190915 100mg, GSK2190915 300mg or placebo tablets administered once daily to fluticasone propionate 100mcg inhalation administered twice daily in uncontrolled asthmatic subjects > or = 12 years of age over the course of 6 weeks treatment.

The secondary objectives are to undertake an exploratory analysis of the efficacy and safety of adding montelukast 10mg administered once daily or salmeterol 50mcg administered twice daily to fluticasone propionate 100mcg inhalation administered twice daily and to investigate the pharmacokinetics and pharmacodynamics of GSK2190915 in uncontrolled asthmatic subjects > or = 12 years of age over the course of 6 weeks treatment.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • GSK2190915
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 12 years of age or older
  • Non-, former or current smokers with a documented smoking history of ≤ 10 pack years
  • Asthma diagnosis as defined by the National Institutes of Health
  • Best of 50% to \<80% of the predicted normal value
  • Post-albuterol FEV1/FVC ratio of >0.70 at Visit 1/1a (between 5:00AM and 12:00 noon)
  • ≥ 12% and ≥200mL reversibility of FEV1
  • Must have been using FP 100mcg inhalation powder BID for at least 2 weeks just prior to Visit 1.
  • Must be able to replace their current short-acting beta2-agonists with albuterol inhalation aerosol
  • Must be able and willing to give written to take part in the study.
  • Must be able and willing to comply with all aspects of the study including completion of daily e-Diary.

Exclusion criteria

Exclusion criteria:

  • History of life-threatening asthma
  • Recent asthma exacerbation
  • Concurrent respiratory disease
  • Recent respiratory infection
  • Liver disease
  • Other concurrent diseases/abnormalities
  • Oral candidiasis
  • Drug allergy
  • Milk protein allergy
  • Medications
  • Administration of systemic, oral or depot within 12 weeks of Visit 1
  • OATP1B1 substrates within 4 weeks of Visit 1
  • Cytochrome P450 3A4 (CYP 3A4) Inhibitors
  • Cytochrome P450 3A4 (CYP 3A4) Inducers
  • Medications
  • Compliance: any infirmity, disability, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol
  • Affiliation with Investigator's Site
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    FP 100mcg BID plus GSK2190915 100mg QD (AM)

    FP 100mcg BID plus GSK2190915 100mg QD (AM)

    Drug: FP 100 · Drug: GSK2190915 100

  • Experimental
    FP 100mcg BID plus GSK2190915 300mg QD (AM)

    FP 100mcg BID plus GSK2190915 300mg QD (AM)

    Drug: FP 100 · Drug: GSK2190915 300

  • Active comparator
    FP 100mcg BID plus montelukast 10mg QD (PM)

    FP 100mcg BID plus montelukast 10mg QD (PM)

    Drug: FP 100 · Drug: montelukast

  • Active comparator
    FP 100mcg BID plus placebo BID

    FP 100mcg BID plus placebo BID

    Drug: FP 100 · Drug: placebo

  • Active comparator
    FP/SAL 100/50mcg BID plus placebo BID

    FP/SAL 100/50mcg BID plus placebo BID

    Drug: placebo · Drug: FP/SAL 100/50

Interventions

  • DrugFP 100

    FP 100mcg BID

  • GSK2190915 100mg QD (AM)

  • GSK2190915 300mg QD (AM)

  • montelukast 10mg QD (PM)

  • Drugplacebo

    placebo BID

  • DrugFP/SAL 100/50

    FP/SAL 100/50mcg BID

06

What researchers measure

Primary outcomes

  1. Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically using spirometry, prior to study medication and any rescue albuterol (bronchodilator) use. At the end of the 6-week treatment period, FEV1 was measured approximately 24 hours after the participant's last morning dose of study medication and approximately 12 hours after the evening dose of study medication. Trough FEV1 was analyzed using mixed effect analysis of covariance (ANCOVA) model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effect of participant. Intent-to-Treat Population is defined as all participants who were randomized and received at least one dose of study drug.

    Time frame: End of Week 6

Secondary outcomes

  1. Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period

    The PEF is a measure of lung function and measures how fast a person can breathe out. Trough PEF was measured every morning prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily electronic diary (eDiary). Daily trough morning PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  2. Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period

    The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  3. Daily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups

    The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every morning and evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily average of morning and evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. This outcome measure explored the efficacy between GSK2190915 and montelukast due to the dosing time difference.

    Time frame: Week 4 to Week 6

  4. Daily Asthma Symptom Score Averaged Over the Last 3 Weeks of the 6-week Treatment Period

    Daytime and night time asthma symptoms were recorded every evening at bedtime and every morning upon rising, respectively, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on scales ranging from '0' (implying no symptoms) to either 5 (for daytime symptoms) or 4 (for night time symptoms) (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. 24-hour period asthma symptom scores were averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  5. Daily Rescue Short-acting beta2-agonist (SABA) Use Averaged Over the Last 3 Weeks of the 6-week Treatment Period

    A SABA (albuterol) was provided to participants as a rescue medication, to use as needed for symptomatic relief of asthma symptoms. Participants were required to record their albuterol use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The daily rescue SABA use was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  6. Percentage of Symptom-free Days During the Last 3 Weeks of the 6-week Treatment Period

    Daytime asthma symptoms were recorded every evening at bedtime, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 6-point scale ranging from '0' (implying no symptoms) to 5 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of days when symptoms were not experienced ("symptom-free days") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  7. Percentage of Symptom-free Nights During the Last 3 Weeks of the 6 Week Treatment Period

    Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale ranging from '0' (implying no symptoms) to 4 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of nights when symptoms were not experienced ("symptom-free nights") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  8. Percentage of Rescue-free Days During the Last 3 Weeks of the 6-week Treatment Period

    Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of days when rescue medication was not used ("rescue-free days") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  9. Percentage of Rescue-free Nights During the Last 3 Weeks of the 6-week Treatment Period

    Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of nights when rescue medication was not used ("rescue-free nights") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  10. Percentage of Nights Without Awakenings Due to Asthma During the Last 3 Weeks of the 6-week Treatment Period

    Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale: 0 = no symptoms during the night, 1 = symptoms causing to wake once, 2 = symptoms causing to wake twice or more, 3 = symptoms causing to be awake most of the night, 4 = could not sleep due to severe symptoms. Participants recorded the symptoms in a daily eDiary. The number of nights with no awakenings due to asthma during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

    Time frame: Week 4 to Week 6

  11. Number of Participants Withdrawn Due to Lack of Efficacy During the Last 3 Weeks of the 6-week Treatment Period

    Participants were withdrawn if they met any of the following three criteria for 'lack of efficacy': 1) Clinic FEV1 below the FEV1 'Stability Limit' value, 2) During any consecutive 7-day period, the participant experienced PEF fallen below the PEF 'Stability Limit' for more than 3 days, or if \>= 12 inhalations per day of albuterol were used for more than 2 days, and 3) Ashtma exacerbation. The number of withdrawals due to lack of efficacy were summarized for each treatment and Fisher's Exact test was used for comparison with placebo add-on. Withdrawals occurring during active washout periods are not included.

    Time frame: Week 4 to Week 6

07

Results

Posted Feb 3, 2017

Participant flow

A total of 341 participants (par.) were screened, and 162 participants were randomized. A protocol amendment necessitated withdrawal of all male participants and further enrollment of female participants only.

Participant flow — Overall Study
MilestoneAll Treatments Combined
Started162
Completed93
Not completed69
Withdrew: Adverse event1
Withdrew: Lack of efficacy36
Withdrew: Protocol violation6
Withdrew: Lost to follow-up3
Withdrew: Physician decision3
Withdrew: Withdrawal by subject9
Withdrew: Other sponsor decision (protocol amendme11

Outcome measures

PrimaryTrough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically using spirometry, prior to study medication and any rescue albuterol (bronchodilator) use. At the end of the 6-week treatment period, FEV1 was measured approximately 24 hours after the participant's last morning dose of study medication and approximately 12 hours after the evening dose of study medication. Trough FEV1 was analyzed using mixed effect analysis of covariance (ANCOVA) model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effect of participant. Intent-to-Treat Population is defined as all participants who were randomized and received at least one dose of study drug.

Time frame:
End of Week 6
Reported as:
Least squares mean · Liters (L)
Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period
Liters (L)FP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period2.36 ± 0.032.39 ± 0.032.40 ± 0.032.42 ± 0.032.43 ± 0.03
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.268 · Mean difference (final values): 0.026 · 95% CI -0.02 to 0.07
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.080 · Mean difference (final values): 0.042 · 95% CI -0.00 to 0.09
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.017 · Mean difference (final values): 0.056 · 95% CI 0.01 to 0.10
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.002 · Mean difference (final values): 0.074 · 95% CI 0.03 to 0.12
SecondaryDaily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period

The PEF is a measure of lung function and measures how fast a person can breathe out. Trough PEF was measured every morning prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily electronic diary (eDiary). Daily trough morning PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Liters/minute (L/min)
Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period
Liters/minute (L/min)FP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period349.19 ± 4.08350.14 ± 4.06354.96 ± 4.07354.17 ± 4.05361.33 ± 4.05
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.751 · Mean difference (final values): 0.946 · 95% CI -4.91 to 6.81
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.049 · Mean difference (final values): 5.771 · 95% CI 0.03 to 11.51
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.123 · Mean difference (final values): 4.983 · 95% CI -1.35 to 11.32
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 12.140 · 95% CI 5.93 to 18.35
SecondaryDaily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period

The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · L/min
Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period
L/minFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period354.06 ± 4.03355.71 ± 4.02359.16 ± 4.03358.88 ± 4.01364.35 ± 4.00
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.563 · Mean difference (final values): 1.651 · 95% CI -3.97 to 7.27
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.072 · Mean difference (final values): 5.100 · 95% CI -0.47 to 10.67
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.126 · Mean difference (final values): 4.822 · 95% CI -1.37 to 11.02
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.001 · Mean difference (final values): 10.292 · 95% CI 4.21 to 16.38
SecondaryDaily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups

The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every morning and evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily average of morning and evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. This outcome measure explored the efficacy between GSK2190915 and montelukast due to the dosing time difference.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · L/min
Daily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups
L/minFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + Montelukast
Daily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups352.37 ± 3.90356.16 ± 3.91356.52 ± 3.90
Statistical analysis
  • FP + GSK2190915 100 mg vs FP + Montelukast · Mean difference (final values): -4.154 · 95% CI -9.36 to 1.06
  • FP + GSK2190915 300 mg vs FP + Montelukast · Mean difference (final values): -0.364 · 95% CI -6.22 to 5.50
SecondaryDaily Asthma Symptom Score Averaged Over the Last 3 Weeks of the 6-week Treatment Period

Daytime and night time asthma symptoms were recorded every evening at bedtime and every morning upon rising, respectively, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on scales ranging from '0' (implying no symptoms) to either 5 (for daytime symptoms) or 4 (for night time symptoms) (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. 24-hour period asthma symptom scores were averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Score on a scale
Daily Asthma Symptom Score Averaged Over the Last 3 Weeks of the 6-week Treatment Period
Score on a scaleFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Daily Asthma Symptom Score Averaged Over the Last 3 Weeks of the 6-week Treatment Period2.26 ± 0.122.26 ± 0.122.15 ± 0.122.22 ± 0.122.25 ± 0.12
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.957 · Mean difference (final values): -0.005 · 95% CI -0.18 to 0.17
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.213 · Mean difference (final values): -0.108 · 95% CI -0.28 to 0.06
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.647 · Mean difference (final values): -0.038 · 95% CI -0.20 to 0.12
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.894 · Mean difference (final values): -0.011 · 95% CI -0.17 to 0.15
SecondaryDaily Rescue Short-acting beta2-agonist (SABA) Use Averaged Over the Last 3 Weeks of the 6-week Treatment Period

A SABA (albuterol) was provided to participants as a rescue medication, to use as needed for symptomatic relief of asthma symptoms. Participants were required to record their albuterol use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The daily rescue SABA use was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Number of inhalations
Daily Rescue Short-acting beta2-agonist (SABA) Use Averaged Over the Last 3 Weeks of the 6-week Treatment Period
Number of inhalationsFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Daily Rescue Short-acting beta2-agonist (SABA) Use Averaged Over the Last 3 Weeks of the 6-week Treatment Period2.17 ± 0.132.14 ± 0.132.03 ± 0.132.09 ± 0.132.08 ± 0.13
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.811 · Mean difference (final values): -0.025 · 95% CI -0.23 to 0.18
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.200 · Mean difference (final values): -0.133 · 95% CI -0.34 to 0.07
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.415 · Mean difference (final values): -0.076 · 95% CI -0.26 to 0.11
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.358 · Mean difference (final values): -0.084 · 95% CI -0.26 to 0.10
SecondaryPercentage of Symptom-free Days During the Last 3 Weeks of the 6-week Treatment Period

Daytime asthma symptoms were recorded every evening at bedtime, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 6-point scale ranging from '0' (implying no symptoms) to 5 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of days when symptoms were not experienced ("symptom-free days") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Percentage of days
Percentage of Symptom-free Days During the Last 3 Weeks of the 6-week Treatment Period
Percentage of daysFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Percentage of Symptom-free Days During the Last 3 Weeks of the 6-week Treatment Period30.84 ± 3.0433.51 ± 3.0236.14 ± 3.0334.88 ± 3.0135.45 ± 3.02
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.285 · Mean difference (final values): 2.666 · 95% CI -2.24 to 7.57
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.035 · Mean difference (final values): 5.300 · 95% CI 0.38 to 10.22
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.090 · Mean difference (final values): 4.036 · 95% CI -0.63 to 8.70
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.047 · Mean difference (final values): 4.602 · 95% CI 0.06 to 9.14
SecondaryPercentage of Symptom-free Nights During the Last 3 Weeks of the 6 Week Treatment Period

Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale ranging from '0' (implying no symptoms) to 4 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of nights when symptoms were not experienced ("symptom-free nights") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Percentage of nights
Percentage of Symptom-free Nights During the Last 3 Weeks of the 6 Week Treatment Period
Percentage of nightsFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Percentage of Symptom-free Nights During the Last 3 Weeks of the 6 Week Treatment Period37.21 ± 2.8738.22 ± 2.8540.55 ± 2.8537.70 ± 2.8438.47 ± 2.85
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.668 · Mean difference (final values): 1.014 · 95% CI -3.64 to 5.67
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.156 · Mean difference (final values): 3.349 · 95% CI -1.29 to 7.98
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.822 · Mean difference (final values): 0.496 · 95% CI -3.83 to 4.82
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.555 · Mean difference (final values): 1.260 · 95% CI -2.94 to 5.46
SecondaryPercentage of Rescue-free Days During the Last 3 Weeks of the 6-week Treatment Period

Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of days when rescue medication was not used ("rescue-free days") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Percentage of days
Percentage of Rescue-free Days During the Last 3 Weeks of the 6-week Treatment Period
Percentage of daysFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Percentage of Rescue-free Days During the Last 3 Weeks of the 6-week Treatment Period40.44 ± 3.0542.43 ± 3.0342.59 ± 3.0442.77 ± 3.0241.96 ± 3.03
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.367 · Mean difference (final values): 1.992 · 95% CI -2.35 to 6.33
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.332 · Mean difference (final values): 2.147 · 95% CI -2.20 to 6.49
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.277 · Mean difference (final values): 2.331 · 95% CI -1.88 to 6.55
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.467 · Mean difference (final values): 1.521 · 95% CI -2.59 to 5.63
SecondaryPercentage of Rescue-free Nights During the Last 3 Weeks of the 6-week Treatment Period

Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of nights when rescue medication was not used ("rescue-free nights") during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Percentage of nights
Percentage of Rescue-free Nights During the Last 3 Weeks of the 6-week Treatment Period
Percentage of nightsFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Percentage of Rescue-free Nights During the Last 3 Weeks of the 6-week Treatment Period45.12 ± 2.8745.69 ± 2.8548.79 ± 2.8645.32 ± 2.8543.98 ± 2.85
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.789 · Mean difference (final values): 0.575 · 95% CI -3.65 to 4.80
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.087 · Mean difference (final values): 3.669 · 95% CI -0.54 to 7.87
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.923 · Mean difference (final values): 0.200 · 95% CI -3.84 to 4.24
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.571 · Mean difference (final values): -1.137 · 95% CI -5.08 to 2.81
SecondaryPercentage of Nights Without Awakenings Due to Asthma During the Last 3 Weeks of the 6-week Treatment Period

Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale: 0 = no symptoms during the night, 1 = symptoms causing to wake once, 2 = symptoms causing to wake twice or more, 3 = symptoms causing to be awake most of the night, 4 = could not sleep due to severe symptoms. Participants recorded the symptoms in a daily eDiary. The number of nights with no awakenings due to asthma during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · Percentage of nights
Percentage of Nights Without Awakenings Due to Asthma During the Last 3 Weeks of the 6-week Treatment Period
Percentage of nightsFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Percentage of Nights Without Awakenings Due to Asthma During the Last 3 Weeks of the 6-week Treatment Period37.21 ± 2.8738.22 ± 2.8540.55 ± 2.8537.70 ± 2.8438.47 ± 2.85
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Mixed Models Analysis · p = =0.668 · Mean difference (final values): 1.014 · 95% CI -3.64 to 5.67
  • FP + Placebo vs FP + GSK2190915 300 mg · Mixed Models Analysis · p = =0.156 · Mean difference (final values): 3.349 · 95% CI -1.29 to 7.98
  • FP + Placebo vs FP + Montelukast · Mixed Models Analysis · p = =0.822 · Mean difference (final values): 0.496 · 95% CI -3.83 to 4.82
  • FP + Placebo vs FP / Salmeterol · Mixed Models Analysis · p = =0.555 · Mean difference (final values): 1.260 · 95% CI -2.94 to 5.46
SecondaryNumber of Participants Withdrawn Due to Lack of Efficacy During the Last 3 Weeks of the 6-week Treatment Period

Participants were withdrawn if they met any of the following three criteria for 'lack of efficacy': 1) Clinic FEV1 below the FEV1 'Stability Limit' value, 2) During any consecutive 7-day period, the participant experienced PEF fallen below the PEF 'Stability Limit' for more than 3 days, or if \>= 12 inhalations per day of albuterol were used for more than 2 days, and 3) Ashtma exacerbation. The number of withdrawals due to lack of efficacy were summarized for each treatment and Fisher's Exact test was used for comparison with placebo add-on. Withdrawals occurring during active washout periods are not included.

Time frame:
Week 4 to Week 6
Reported as:
Number · Number of participants
Number of Participants Withdrawn Due to Lack of Efficacy During the Last 3 Weeks of the 6-week Treatment Period
Number of participantsFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Number of Participants Withdrawn Due to Lack of Efficacy During the Last 3 Weeks of the 6-week Treatment Period95375
Statistical analysis
  • FP + Placebo vs FP + GSK2190915 100 mg · Fisher Exact · p = =0.408
  • FP + Placebo vs FP + GSK2190915 300 mg · Fisher Exact · p = =0.138
  • FP + Placebo vs FP + Montelukast · Fisher Exact · p = =0.797
  • FP + Placebo vs FP / Salmeterol · Fisher Exact · p = =0.408

Adverse events

Collected over On-treatment adverse events (AE) and serious adverse events (SAE) were collected from the start of treatment until the follow-up contact (a maximum of 178 days).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FP + Placebo—0/104 (0%)8/104 (7.7%)
FP + GSK2190915 100 mg—1/103 (1%)3/103 (2.9%)
FP + GSK2190915 300 mg—0/96 (0%)4/96 (4.2%)
FP + Montelukast—0/99 (0%)1/99 (1%)
FP / Salmeterol—0/104 (0%)1/104 (1%)
Most frequent serious events
Most frequent serious events
EventFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
Intestinal obstructionGastrointestinal disorders0/1041/1030/960/990/104
Most frequent other events
Most frequent other events
EventFP + PlaceboFP + GSK2190915 100 mgFP + GSK2190915 300 mgFP + MontelukastFP / Salmeterol
NasopharyngitisRespiratory, thoracic and mediastinal disorders6/1041/1031/961/991/104
SinusitisRespiratory, thoracic and mediastinal disorders2/1042/1033/960/990/104

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Treatments Combined
Mean36.8 ± 14.43
Sex: Female, Male
Sex: Female, Male(Participants)All Treatments Combined
Female151
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Treatments Combined
African American/African Heritage42
American Indian or Alaska Native1
Asian - Central/South Asian Heritage1
White - White/Caucasian/European Heritage115
Mixed Race2
Missing1
08

Study locations

32 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46208, United States
  • GSK Investigational Site
    Lenexa, Kansas 66215, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Bangor, Maine 04401, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    St. Louis, Missouri 63141, United States
  • GSK Investigational Site
    Bellevue, Nebraska 68123-4303, United States
  • GSK Investigational Site
    Ocean, New Jersey 07712, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18020, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    Plano, Texas 75024, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Snowise NG, Clements D, Ho SY, Follows RM. Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma. Curr Med Res Opin. 2013 Dec;29(12):1663-74. doi: 10.1185/03007995.2013.842163. Epub 2013 Sep 19. PubMed 24010736 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 5 years 4 months after primary completion. A results delay was requested in Apr 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2010
First posted
Jul 5, 2010
Start
Sep 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results delay requested
Apr 12, 2012
Results first posted
Feb 3, 2017
Last update
Apr 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01156792
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 5, 2010
Start date
Sep 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Feb 3, 2017
Last update
Apr 5, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion